BTNL3/8 Targeting Protein Constructs for Gastrointestinal Delivery

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

There is a need for localized delivery of pharmaceutical agents to the gastrointestinal system, particularly to BTNL3/8 expressing cells in the intestinal epithelia, to treat diseases such as inflammatory bowel diseases, while minimizing toxicity by avoiding exposure to off-target tissues.

Innovation Solution

The development of a protein construct comprising a BTNL3/8 targeting moiety, a payload, and an optional linker, where the BTNL3/8 targeting moiety specifically binds to BTNL3/8 proteins, allowing for targeted delivery of therapeutic agents to BTNL3/8 expressing cells in the gastrointestinal tract.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If systemic delivery of pharmaceutical agents is used, then sufficient concentration at the pathological site can be achieved, but significant toxicity occurs in off-target tissues

Engineering Contradiction:

Improveconcentration at pathological siteVSAvoidtoxicity in off-target tissues

Core Design Contradiction:

ReliabilityVSObject-affected harmful factors

Solution Approach 1:

The patent applies local quality by creating a targeting moiety with specific binding characteristics that localizes the pharmaceutical agent to BTNL3/8 expressing cells in the gastrointestinal tract. The targeting moiety is designed with specific affinity and selectivity for BTNL3/8, ensuring the payload concentrates at the pathological site while minimizing systemic exposure and toxicity in off-target tissues.

Inventive Principle:

Principle #3Local quality

Solution Approach 2:

The patent uses an intermediary approach by introducing a targeting moiety as a mediator between the pharmaceutical payload and BTNL3/8 expressing cells. This targeting moiety acts as a bridge that specifically binds to BTNL3/8 proteins on the cell surface, facilitating localized delivery of the payload to the desired tissue while preventing random distribution throughout the body.

Inventive Principle:

Principle #24Intermediary (Mediator)

2Object-affected harmful factors

If targeted delivery to BTNL3/8 expressing cells is achieved, then toxicity is reduced, but the complexity of the delivery system increases

Engineering Contradiction:

ImprovetoxicityVSAvoidcomplexity of delivery system

Core Design Contradiction:

Object-affected harmful factorsVSDevice complexity

Solution Approach 1:

The patent applies segmentation by dividing the delivery system into distinct functional modules: a targeting moiety component and a payload component. The targeting moiety is designed as a separate, well-defined unit that can be independently optimized for binding to BTNL3/8, while the payload contains the pharmaceutical agent. This modular segmentation allows for simplified design and manufacturing of each component while achieving complex targeted delivery functionality.

Inventive Principle:

Principle #1Segmentation

Applied Scientific Principles

This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.

Function Achieved in This Case

This approach enables selective targeting and delivery of therapeutic payloads to BTNL3/8 expressing cells, potentially reducing systemic toxicity and enhancing the efficacy of treatments for gastrointestinal disorders by ensuring localized action.

Implementation Method 1

the BTNL3/8 targeting moiety specifically binds to BTNL3/8 proteins

Methodology Applied

Scientific EffectSpecific binding:

Data Source

PatentUS20250122264A1BTNL3/8 targeting constructs for delivery of payloads to the gastrointestinal system

Publication Date: 2025.04.17 GAMMADELTA THERAPEUTICS LTD

AI summary

Protein constructs comprising a BTNL 3/8 targeting moiety, a payload and an optional linker are described herein. Pharmaceutical compositions comprising the constructs, and methods of use thereof are presented.